公开(公告)号：US20220177597A1

公开(公告)日：2022-06-09

申请号：US17255378

申请日：2019-06-19

Applicant: Ossianix, Inc.

Inventor： Krzysztof Bartlomiej Wicher ,  Jaroslaw Michal Szary ,  Julia Lynn Rutkowski ,  Fabrizio Comper ,  Pawel Stocki

IPC: C07K16/28 ,  C40B30/04 ,  A61P35/00

Abstract: The present invention relates to CD98hc binding moieties with high specificity and with ability to cross the blood brain barrier (BBB). Such moieties may be used alone or as components in specific conjugates that target the amino acid transporter complexes formed with a light chain and CD98hc. The invention relates more specifically to VNAR single chain antibodies derived from nurse shark that bind to CD98hc, compounds and compositions comprising a CD98hc-specific binding moiety, diagnostic and therapeutic methods of use in vitro or in vivo, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier by association with a CD98hc-specific VNAR binding moiety. The invention also includes Type IV semi-synthetic VNAR libraries derived from shark VNARs for selection of binding moieties that specifically bind to a molecular or cellular target of interest.

公开(公告)号：US11345742B1

公开(公告)日：2022-05-31

申请号：US17343444

申请日：2021-06-09

Applicant: Ossianix, Inc.

Inventor： Aziz Gauhar ,  Cyril V. Privezentzev ,  Pawel Stocki ,  Julia Lynn Rutkowski

IPC: C07K16/10 ,  A61P31/14

Abstract: The present disclosure provides coronavirus S1-fragment specific binding moieties comprising Type II VNAR domains, VNAR antibodies, methods of using those moieties and antibodies to treat COVID-19. In some embodiments, a VNAR antibody, originally selected from a phage display library as a VNAR clone using S1fragments from the SARS-CoV-2 Wuhan strain, are also effective at specifically binding to and/or neutralizing SARS-CoV-2 and certain SARS-CoV-2 mutants.

公开(公告)号：US11339389B2

公开(公告)日：2022-05-24

申请号：US16592017

申请日：2019-10-03

Applicant: Ossianix, Inc.

Inventor： Julien Häsler ,  Julia Lynn Rutkowski

IPC: C40B40/10 ,  C12N15/10 ,  C07K16/28 ,  C07K16/00 ,  C07K16/22 ,  C40B40/08

Abstract: The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.

公开(公告)号：US20220031857A1

公开(公告)日：2022-02-03

申请号：US17381775

申请日：2021-07-21

Applicant: Ossianix, Inc.

Inventor： Pawel STOCKI ,  Krzysztof Bartlomiej WICHER ,  Julia Lynn RUTKOWSKI ,  Fabrizio COMPER ,  Mykhaylo DEMYDCHUK ,  Jaroslaw Michal SZARY

IPC: A61K47/64 ,  G01N33/68 ,  C07K16/28 ,  C07K16/40 ,  C12N15/10 ,  C12N15/09 ,  G01N33/58 ,  A61K47/56 ,  C12N15/113

Abstract: The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.

公开(公告)号：US20170198281A1

公开(公告)日：2017-07-13

申请号：US15321314

申请日：2015-06-26

Applicant: Ossianix, Inc.

Inventor： Julien HÄSLER ,  Julia Lynn RUTKOWSKI

IPC: C12N15/10 ,  C07K16/00 ,  C07K16/22 ,  C07K16/28

CPC classification number: C12N15/1055 ,  C07K16/00 ,  C07K16/005 ,  C07K16/22 ,  C07K16/2875 ,  C07K16/2881 ,  C07K2317/20 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/72 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12N15/1037 ,  C40B40/08

Abstract: The present invention relates to VNAR single chain antibodies and more particularly, to semi-synthetic VNAR libraries derived from nurse shark which may be used to identify individual clones, nucleic acid molecules and polypeptides which encode binding moieties that specifically bind to a cellular target of interest, thereby altering (e.g., antagonizing) target activity in a cell or mimicking the activity of a native molecule. The present invention thus also relates to compounds and compositions comprising a target specific VNAR binding moiety, methods for preparing them, and diagnostic and therapeutic methods of use relating to regulation, e.g., agonism or antagonism of the selected cellular target or target pathway e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to alter, e.g., agonize or augment, antagonize, reduce or eliminate the specific cellular target activity.